中草药

中药抗肝纤维化研究进展

PDF下载

中草药 | 中药防治器官纤维化研究 2026,57(18): 7086-7096

收起

中草药 |中药防治器官纤维化研究 2026 , 57 (18) : 7086 -7096

中药抗肝纤维化研究进展

全屏

周璇¹, 赵文朵¹, 王祖驰¹, 齐双², 李肖¹

作者信息

通讯作者:

齐双

作者简介:

周璇: 周璇，硕士研究生，研究方向为中药药效物质基础。E-mail:18253518815@163.com

Research progress on traditional Chinese medicine against liver fibrosis

ZHOU Xuan¹, ZHAO Wenduo¹, WANG Zuchi¹, QI Shuang², LI Xiao¹

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.18.002

文章导航

摘要

收起

肝纤维化是肝脏内的慢性损伤修复反应，其本质为肝脏细胞外基质（extracellular matrix，ECM）的弥漫性过度沉积与异常分布。尽管病因治疗可延缓纤维化进展，但直接靶向纤维化过程的药物研发仍面临重大挑战，临床选择极为有限。中医药凭借多成分、多靶点、多通路的特点，在抗肝纤维化领域受到广泛关注，但相关研究仍以基础实验为主，系统性的机制整合与临床证据梳理尚不充分。通过概述肝纤维化的发病机制，重点阐述肝巨噬细胞极化、肝窦内皮细胞毛细血管化、肝星状细胞活化及ECM代谢失衡等机制；按类别归纳中药活性成分的抗肝纤维化作用规律，从炎症启动、代谢调节、肝纤维化执行3个层级整合信号通路的交互网络，探讨中药多成分协同调控的抗肝纤维化系统机制；并对多组学整合、单细胞测序、人工智能筛选及病因分型精准治疗等前沿技术驱动下的研究方向进行展望，为中药抗肝纤维化的机制阐释与临床转化提供思路。

关键词

中药 / 肝纤维化 / 肝巨噬细胞 / 肝星状细胞 / 细胞外基质

Abstract

收起

Liver fibrosis is a chronic wound-healing response of the liver, essentially characterized by diffuse excessive deposition and abnormal distribution of the extracellular matrix (ECM). Although etiological therapy can slow fibrosis progression, drug development directly targeting the fibrotic process still faces substantial challenges, and clinical options remain extremely limited. Traditional Chinese medicine (TCM) has attracted extensive attention in the field of liver fibrosis research due to its multi-component, multi-target, and multi-pathway properties. However, current studies are still predominantly based on preclinical experiments, and systematic integration of mechanisms and sorting of clinical evidence are still inadequate. This review outlines the pathogenesis of liver fibrosis, with emphasis on the polarization of Kupffer cells, the capillarization of liver sinusoidal endothelial cells, the activation of hepatic stellate cells, and ECM metabolic imbalance. Antifibrotic effects of active components from herbs are summarized by chemical categories. Furthermore, the interactive network of signaling pathways is integrated from three hierarchical levels—the “inflammation initiation, metabolic regulation, and fibrotic progression”—to explore the systemic mechanisms underlying synergistic modulation by multiple components of TCM. Finally, the limitations of current research are identified, and future directions driven by cutting-edge technologies, including multi-omics integration, single-cell sequencing, artificial intelligence-based screening, and etiology-stratified precision therapy, are discussed. This review provides insights into mechanism interpretation and clinical translation of TCM against liver fibrosis.

Key words

traditional Chinese medicine / liver fibrosis / Kupffer cells / hepatic stellate cells / extracellular matrix

引用本文

周璇, 赵文朵, 王祖驰, 齐双, 李肖. 中药抗肝纤维化研究进展. 中草药, 2026 , 57 (18) : 7086 -7096 . DOI: 10.7501/j.issn.0253-2670.2026.18.002

ZHOU Xuan, ZHAO Wenduo, WANG Zuchi, QI Shuang, LI Xiao. Research progress on traditional Chinese medicine against liver fibrosis[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (18) : 7086 -7096 . DOI: 10.7501/j.issn.0253-2670.2026.18.002

基金

收起

国家自然科学基金资助项目 (82204656); 博士后科学基金特别资助 (2024T170534); 山东省中医药科技项目 (M20241725); 山东中医药大学中医药特色专项 (KY2025T09); 山东省自然科学基金面上项目 (ZR2026MS1262)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

李依洁,贾可欣,刘闰平,等.五法经典方辨治肝纤维化的现代药理作用研究概况[J]. 中草药, 2022, 53(16):5193-5204.
Horn P, Tacke F. Metabolic reprogramming in liver fibrosis[J]. Cell Metab, 2024, 36(7):1439-1455.
He X, Wang Y G, Fan X B, et al. A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III[J]. J Hepatol, 2020, 72(3):519-527.
Lytvyak E, Hirschfield G, Shreekumar D, et al.Pathogenesis, non-invasive assessments and treatment of hepatic fibrosis in autoimmune liver diseases[J]. Liver Int,2025, 45(8):e70190.
Dawood R M, El-Meguid M A, Salum G M, et al. Key players of hepatic fibrosis[J]. J Interf Cytokine Res, 2020,40(10):472-489.
Zamani M, Alizadeh-Tabari S, Ajmera V, et al. Global prevalence of advanced liver fibrosis and cirrhosis in the general population:A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2025, 23(7):1123-1134.
Lin M H, Li H Q, Zhu L, et al. Liver fibrosis in the natural course of chronic hepatitis B viral infection:A systematic review with meta-analysis[J]. Dig Dis Sci, 2022, 67(6):2608-2626.
陈玲,郑群,谢玲俐,等. MC4R-rs6567160位点基因多态性与非酒精性脂肪性肝病患者纤维化程度的相关性[J]. 中西医结合肝病杂志, 2026, 36(5):564-568.
钱建丹,赵鸿,王贵强.慢性乙型肝炎肝纤维化/肝硬化的治疗现状[J]. 临床肝胆病杂志, 2021, 37(12):2909-2913.
Jangra A, Kothari A, Sarma P, et al. Recent advancements in antifibrotic therapies for regression of liver fibrosis[J]. Cells, 2022, 11(9):1500.
黄健,宫雪晴,曾颜,等.肝纤维化治疗药物的研究进展[J]. 临床肝胆病杂志, 2025, 41(10):2141-2148.
Zhao L T, Tang H L, Cheng Z J. Pharmacotherapy of liver fibrosis and hepatitis:Recent advances[J]. Pharmaceuticals, 2024, 17(12):1724.
Cerrito L, Galasso L, Iaccarino J, et al. Present and future perspectives in the treatment of liver fibrosis[J]. Pharmaceuticals, 2025, 18(9):1321.
施梅姐,萧焕明,谢玉宝,等.中医药防治慢性乙型肝炎肝纤维化的现状、挑战与思考[J]. 临床肝胆病杂志,2023, 39(6):1280-1286.
李开楊,杨梅,卢娜,等.基于网络药理学探讨中药及其有效成分在治疗肝纤维化中的作用[J]. 中国医药导刊, 2025, 27(8):814-820.
靳福星,张伟,王婧雯,等.中药干预肝纤维化研究的文献计量学分析:现状、热点与展望[J]. 中草药,2025, 56(16):5906-5924.
Roehlen N, Crouchet E, Baumert T F. Liver fibrosis:Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4):875.
Khanam A, Saleeb P G, Kottilil S. Pathophysiology and treatment options for hepatic fibrosis:Can it be completely cured?[J]. Cells, 2021, 10(5):1097.
Akkız H, Gieseler R K, Canbay A. Liver fibrosis:From basic science towards clinical progress, focusing on the central role of hepatic stellate cells[J]. Int J Mol Sci, 2024,25(14):7873.
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):151-166.
Lee Y A, Wallace M C, Friedman S L. Pathobiology of liver fibrosis:A translational success story[J]. Gut, 2015,64(5):830-841.
Zoubek M E, Trautwein C, Strnad P. Reversal of liver fibrosis:From fiction to reality[J]. Best Pract Res Clin Gastroenterol, 2017, 31(2):129-141.
Parola M, Pinzani M. Liver fibrosis:Pathophysiology,pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65:37-55.
Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023,20(10):633-646.
Trautwein C, Friedman S L, Schuppan D, et al. Hepatic fibrosis:Concept to treatment[J]. J Hepatol, 2015, 62(1):S15-S24.
Cheng D, Chai J, Wang H W, et al. Hepatic macrophages:Key players in the development and progression of liver fibrosis[J]. Liver Int, 2021, 41(10):2279-2294.
Dai Q Q, Ain Q, Seth N, et al. Liver sinusoidal endothelial cells:Friend or foe in metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis[J]. Dig Liver Dis, 2025, 57(5):493-503.
Zhou J T, Wang J Q, Zhang L J, et al. Defenestration of liver sinusoidal endothelial cells:The trigger of liver fibrosis[J]. Pharmaceuticals, 2025, 18(6):893.
He Q Y, He W, Dong H, et al. Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease[J]. Cell Commun Signal, 2024, 22(1):346.
Qu J R, Wang L, Li Y F, et al. Liver sinusoidal endothelial cell:An important yet often overlooked player in the liver fibrosis[J]. Clin Mol Hepatol, 2024, 30(3):303-325.
Tsuchida T, Friedman S L. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017,14(7):397-411.
Yan M Y, Cui Y M, Xiang Q. Metabolism of hepatic stellate cells in chronic liver diseases:emerging molecular and therapeutic interventions[J]. Theranostics, 2025,15(5):1715-1740.
Chen W, Yang A T, Jia J D, et al. Lysyl oxidase(LOX)family members:Rationale and their potential as therapeutic targets for liver fibrosis[J]. Hepatology, 2020,72(2):729-741.
Abd El-Fattah E E, Zakaria A Y. Targeting HSP47 and HSP70:Promising therapeutic approaches in liver fibrosis management[J]. J Transl Med, 2022, 20(1):544.
Tacke F, Puengel T, Loomba R, et al. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH[J]. J Hepatol, 2023, 79(2):552-566.
马富都,赵唯含,陶娜,等. TLR4信号通路在肝纤维化中的作用及中医药调控机制研究进展[J]. 中西医结合肝病杂志, 2026, 36(5):649-653.
Wang K P, Yang X W, Wu Z J, et al. Dendrobium officinale polysaccharide protected CCl4-induced liver fibrosis through intestinal homeostasis and the LPS-TLR4-NF-κB signaling pathway[J]. Front Pharmacol, 2020, 11:240.
白雅洁,杨柳青,范钦,等.铁皮石斛多糖通过上皮间质转化和Notch信号通路体外抗肝纤维化作用机制[J]. 中国临床药理学与治疗学, 2026, 31(3):337-343.
杨依萍,高琳,陈臻宇,等.多花黄精多糖通过激活Nrf2信号通路抑制铁死亡改善CCl4诱导的小鼠肝纤维化[J/OL]. 中国中药杂志,(2026-06-10)[2026-08-07]. https://doi.org/10.19540/j.cnki.cjcmm.20260609.901.
Zhang K F, Xu Q M, Gao Y, et al. Polysaccharides from Dicliptera chinensis ameliorate liver disturbance by regulating TLR-4/NF-κB and AMPK/Nrf2 signalling pathways[J]. J Cell Mol Med, 2020, 24(11):6397-6409.
尚双艳,高翔.香附多糖对牛血清白蛋白诱导的肝纤维化大鼠血清MMP-2、TIMP-2和TGF-β1水平的影响[J]. 实用肝脏病杂志, 2018, 21(1):42-45.
Chen C J, Chen J J, Wang Y, et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling[J]. Phytomedicine, 2023, 110:154626.
Meng X Q, Kuang H X, Wang Q H, et al. A polysaccharide from Codonopsis pilosula roots attenuates carbon tetrachloride-induced liver fibrosis via modulation of TLR4/NF-κB and TGF-β1/Smad3 signaling pathway[J]. Int Immunopharmacol, 2023, 119:110180.
Nie Y M, Zhou W Q, Niu T, et al. Peptidoglycan isolated from the fruit of Lycium barbarum alleviates liver fibrosis in mice by regulating the TGF-β/Smad7 signaling and gut microbiota[J]. Acta Pharmacol Sin, 2025, 46(5):1329-1344.
Yuan X X, Gong Z Q, Wang B Y, et al. Astragaloside inhibits hepatic fibrosis by modulation of TGF-β1/smad signaling pathway[J]. Evid Based Complement Alternat Med, 2018, 2018:3231647.
方静,胡永红,梁悦,等.黄芪总皂苷抑制胆管反应抗胆汁性肝纤维化的作用机制研究[J]. 世界科学技术-中医药现代化, 2023, 25(7):2327-2335.
Lin L B, Zhou M G, Que R Y, et al. Saikosaponin-D protects against liver fibrosis by regulating the estrogen receptor-β/NLRP3 inflammasome pathway[J]. Biochem Cell Biol, 2021, 99(5):666-674.
Yong Q H, Huang C Y, Chen B N, et al. Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4and NLRP3 signaling pathways[J]. Biomed Pharmacother, 2024, 177:116952.
李瑞麟,马勇,魏伟,等.白芍总苷治疗四氯化碳致大鼠肝纤维化的作用与其影响肝星状细胞功能的关系[J]. 中国新药杂志, 2007, 16(9):685-689.
Liu X X, Mi X J, Wang Z, et al. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway[J]. Cell Death Dis, 2020, 11(6):454.
Xu Y S, Yang C, Zhang S J, et al. Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation[J]. Biol Pharm Bull, 2018,41(11):1638-1644.
Hou Y L, Tsai Y H, Lin Y H, et al. Ginseng extract and ginsenoside Rb1 attenuate carbon tetrachloride-induced liver fibrosis in rats[J]. BMC Complement Altern Med,2014, 14:415.
Hui J, Gao J R, Wang Y Z, et al. Panax notoginseng saponins ameliorates experimental hepatic fibrosis and hepatic stellate cell proliferation by inhibiting the JAK2/STAT3 pathways[J]. J Tradit Chin Med, 2016, 36(2):217-224.
Zhang F, Ni C Y, Kong D S, et al. Ligustrazine attenuates oxidative stress-induced activation of hepatic stellate cells by interrupting platelet-derived growth factor-β receptormediated ERK and p38 pathways[J]. Toxicol Appl Pharmacol, 2012, 265(1):51-60.
Zhang F, Lu S, He J L, et al. Ligand activation of PPARγby ligustrazine suppresses pericyte functions of hepatic stellate cells via SMRT-mediated transrepression of HIF-1α[J]. Theranostics, 2018, 8(3):610-626.
Wang N, Xu Q H, Tan H Y, et al. Berberine inhibition of fibrogenesis in a rat model of liver fibrosis and in hepatic stellate cells[J]. Evid Based Complement Alternat Med,2016, 2016:8762345.
吴鹏,王亚东,蒋怀周,等.小檗碱对铜负荷大鼠肝纤维化组织Notch信号通路的作用研究[J]. 中华中医药杂志, 2018, 33(10):4731-4735.
孟赛,巩林强,李曙晖,等.荷叶碱通过p38 MAPKPPARγ/NF-κB信号通路对肝硬化大鼠的影响[J]. 中国免疫学杂志, 2025, 41(3):595-599.
Yang D M, Li L, Qian S J, et al. Evodiamine ameliorates liver fibrosis in rats via TGF-β1/Smad signaling pathway[J]. J Nat Med, 2018, 72(1):145-154.
Jiang Y, Wang C, Li Y Y, et al. Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-β/Smad interference[J]. J Ethnopharmacol, 2014,158 Pt A:230-238.
Wang R, Zhang H, Wang Y Y, et al. Inhibitory effects of quercetin on the progression of liver fibrosis through the regulation of NF-кB/IкBα, p38 MAPK, and Bcl-2/Bax signaling[J]. Int Immunopharmacol, 2017, 47:126-133.
Wu L W, Zhang Q H, Mo W H, et al. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways[J]. Sci Rep, 2017, 7(1):9289.
Wu X J, Zhi F C, Lun W J, et al. Baicalin inhibits PDGFBB-induced hepatic stellate cell proliferation, apoptosis,invasion, migration and activation via the miR-3595/ACSL4 axis[J]. Int J Mol Med, 2018, 41(4):1992-2002.
Zaghloul R A, Zaghloul A M, El-Kashef D H.Hepatoprotective effect of Baicalin against thioacetamideinduced cirrhosis in rats:Targeting NOX4/NF-κB/NLRP3inflammasome signaling pathways[J]. Life Sci, 2022, 295:120410.
Hernández-Aquino E, Zarco N, Casas-Grajales S, et al.Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways[J]. World J Gastroenterol, 2017, 23(24):4354-4368.
唐尧,欧士钰,杜凌,等.荔枝核总黄酮对猪血清诱导的免疫性肝纤维化大鼠肝脏中EGR1、TGF-β1表达的影响[J]. 陕西中医药大学学报, 2023, 46(6):67-72.
李睿,江扬帆,童琳,等.龙血竭总黄酮对免疫性肝纤维化大鼠肝脏中TGF-β1表达的影响[J]. 安徽医科大学学报, 2019, 54(4):549-553.
王利兵,李雯,李木松.藤茶总黄酮通过TGF-β/Smad通路对肝纤维化小鼠的作用机制研究[J]. 中医药导报, 2022, 28(2):24-29.
Liu F B, Li S N, Chen P P, et al. Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ[J]. Int Immunopharmacol, 2023, 122:110550.
Fu Y D, Zhou X X, Wang L, et al. Salvianolic acid B attenuates liver fibrosis by targeting ECM1 and inhibiting hepatocyte ferroptosis[J]. Redox Biol, 2024, 69:103029.
Chen N Z, Geng Q Q, Zheng J B, et al. Suppression of the TGF-β/Smad signaling pathway and inhibition of hepatic stellate cell proliferation play a role in the hepatoprotective effects of curcumin against alcohol-induced hepatic fibrosis[J]. Int J Mol Med, 2014, 34(4):1110-1116.
Wang Y Q, Li Y J, Qiu Y L, et al. Artesunate induces ferroptosis in hepatic stellate cells and alleviates liver fibrosis via the ROCK1/ATF3 axis[J]. J Clin Transl Hepatol, 2024, 12(1):36-51.
Qin T T, Hasnat M, Wang Z W, et al. Geniposide alleviated bile acid-associated NLRP3 inflammasome activation by regulating SIRT1/FXR signaling in bile duct ligationinduced liver fibrosis[J]. Phytomedicine, 2023, 118:154971.
Xu L J, Zhang Y R, Ji N B, et al. Tanshinone IIA regulates the TGF-β1/Smad signaling pathway to ameliorate nonalcoholic steatohepatitis-related fibrosis[J]. Exp Ther Med, 2022, 24(1):486.
谢婧,李丽华.脱水穿心莲内酯对四氯化碳诱导的肝纤维化模型小鼠肝细胞凋亡的抑制作用及其机制[J]. 吉林大学学报:医学版, 2019, 45(5):1009-1014.
郑洋,卢能源,黄永贤,等.基于TGF-β1/Smad信号通路探讨莪术醇对肝纤维化小鼠作用的实验研究[J]. 中华中医药学刊, 2021, 39(11):149-152.
Yang P C, Bai W Z, Wang J, et al. Sedum sarmentosum total flavonoids alleviate schistosomiasis-induced liver fibrosis by altering TGF-β1 and Smad7 expression[J]. Evid-Based Compl Alt, 2020, 2020:2083697.
付月月,朱兰平,张国梁,等.夏枯草硫酸多糖对CCl4致大鼠肝纤维化及TGF-β1诱导的大鼠肝星状细胞活化的影响[J]. 中国实验方剂学杂志, 2018, 24(14):147-152.
安祯祥,何远利,黄丹,等.金钗石斛多糖对肝纤维化大鼠TGF-β1、α-SMA、I型胶原、III型胶原表达的影响[J]. 中国老年学杂志, 2022, 42(2):381-385.
Shu G W, Yusuf A, Dai C X, et al. Piperine inhibits AML-12 hepatocyte EMT and LX-2 HSC activation and alleviates mouse liver fibrosis provoked by CCl4:Roles in the activation of the Nrf2 cascade and subsequent suppression of the TGF-β1/Smad axis[J]. Food Funct,2021, 12(22):11686-11703.
Guo M M, Wang Z D, Dai J Y, et al. Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway[J]. Phytomedicine, 2023, 112:154587.
Wu J Z, Li Y J, Huang G R, et al. Mechanisms exploration of Angelicae Sinensis Radix and Ligusticum Chuanxiong Rhizoma herb-pair for liver fibrosis prevention based on network pharmacology and experimental pharmacologylogy[J]. Chin J Nat Med, 2021, 19(4):241-254.
Wu M, Zhou Y, Qin S L, et al. Fuzheng Huayu Capsule attenuates hepatic fibrosis by inhibiting activation of hepatic stellate cells[J]. Evid Based Complement Alternat Med, 2020, 2020:3468791.
Wang T, Zhou X L, Liu H H, et al. Fuzheng Huayu Capsule as an adjuvant treatment for HBV-related cirrhosis:A systematic review and Meta-analysis[J]. Phytother Res,2018, 32(5):757-768.
Zhang T Y, Yang Y, Wang B J, et al. Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis B cirrhosis:Protocol of systematic review and meta-analysis[J]. Medicine, 2019, 98(51):e18458.
莫芳妮,舒盼,马永莉.鳖甲煎丸治疗乙型肝炎肝纤维化(肝脾血瘀证)的临床研究[J]. 中华中医药学刊,2026, 44(4):95-99.
王晶,彭芳辰.扶正化瘀胶囊与安络化纤丸治疗慢性乙型肝炎肝纤维化疗效的间接Meta分析[J]. 中国中药杂志, 2018, 43(7):1492-1500.
聂红明,王灵台.安络化纤丸抗肝纤维化的研究进展[J]. 中西医结合肝病杂志, 2016, 26(3):185-187.
牛媛媛,汪龙德,毛兰芳,等.基于网络药理学探讨化瘀软肝胶囊对肝纤维化大鼠的肝脏保护作用[J]. 中成药, 2023, 45(9):3104-3109.
李楠,任素娟,周瑞,等.基于网络药理学及动物实验探讨五灵胶囊抗肝纤维化的作用机制[J]. 中国中药杂志, 2023, 48(19):5365-5376.
周志颖,苏春芝,安泽伟.基于PI3K/Akt通路探讨化浊健脾调肝方对肝纤维化小鼠氧化应激与炎症反应的作用机制[J]. 中西医结合肝病杂志, 2026, 36(5):592-596.
陈世玉,赵鲲鹏,张秋菊,等.基于RhoA/ROCK1信号通路的舒肝和络醒脾方干预肝纤维化模型大鼠作用机制研究[J]. 甘肃中医药大学学报, 2026, 43(3):1-8.
邓嫦,龚俊文,秦德源,等.八珍荔核抗纤方通过COX-2/PGE2/NF-κB信号通路改善CCl4大鼠肝纤维化的机制研究[J]. 时珍国医国药, 2026, 37(10):1861-1869.
代东雪,潘志,唐成芳,等.消癥活络方对肝纤维化大鼠肝组织α-SMA和TGF-β1表达的影响[J]. 吉林中医药, 2017, 37(2):162-166.
田乐,王颖航,潘志.基于网络药理学探讨消癥活络方通过ERK5通路抗大鼠肝纤维化的机制[J]. 临床肝胆病杂志, 2021, 37(3):582-589.
彭孟云,陈然,朱晓宁,等.参仁活血颗粒对四氯化碳诱导的大鼠肝纤维化TGF-β1/Smad信号通路的影响[J]. 中国实验动物学报, 2019, 27(5):631-636.
王志旺,付晓艳,程小丽,等.育阴软肝颗粒剂对肝纤维化大鼠TGF-β1表达的影响[J]. 中国应用生理学杂志, 2018, 34(2):169-172.
韦凌霞,丁茂鹏,王志旺,等.育阴软肝颗粒抗肝纤维化“多成分-多靶点”的网络药理学研究[J]. 中国新药杂志, 2020, 29(7):788-798.
刘晶晶,周小琦,王璐,等.益气活血利水汤调控Nrf2/GPX4信号通路抑制铁死亡改善肝纤维化大鼠的机制研究[J]. 中医药学报, 2026, 54(6):18-24.
张歌瑶,黄玉,张元浩,等.基于TGF-β1/Smads通路探讨柔木丹颗粒对肝纤维化大鼠的作用机制[J]. 长春中医药大学学报, 2026, 42(4):442-449.
Cai F F, Wu R, Song Y N, et al. Yinchenhao decoction alleviates liver fibrosis by regulating bile acid metabolism and TGF-β/smad/ERK signalling pathway[J]. Sci Rep,2018, 8(1):15367.
Liu Z L, Xu B G, Ding Y P, et al. Guizhi Fuling pill attenuates liver fibrosis in vitro and in vivo via inhibiting TGF-β1/Smad2/3 and activating IFN-γ/Smad7 signaling pathways[J]. Bioengineered, 2022, 13(4):9357-9368.
Yao H, He Q M, Xiang L, et al. Guizhi Fuling Wan attenuates tetrachloromethane-induced hepatic fibrosis in rats via PTEN/Akt/mTOR signaling pathway[J]. J Ethnopharmacol, 2024, 334:118593.
Huang Y Z, Lu J, Xu Y L, et al. Xiaochaihu decorction relieves liver fibrosis caused by Schistosoma japonicum infection via the HSP47/TGF-β pathway[J]. Parasit Vectors, 2020, 13(1):254.
俞佳雯,阙任烨,钱春美,等.逍遥散对铁过载诱导的肝纤维化的干预作用及其抑制肝铁过载的分子机制[J]. 中国药理学通报, 2026, 42(7):1385-1392.
耿巧.四逆散通过调控肝内库普弗细胞极化治疗肝纤维化的作用机制研究[D]. 南京:南京中医药大学,2025.

2026年第57卷第18期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.18.002

接收时间：2026-05-19
首发时间：2026-10-29

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-05-19

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.18.002

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT